Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fsd Pharma Inc Cl B (NQ: HUGE )

1.250 -0.120 (-8.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 282,175
Open 1.300
Bid (Size) 1.250 (7)
Ask (Size) 1.330 (2)
Prev. Close 1.370
Today's Range 1.240 - 1.360
52wk Range 0.6181 - 2.100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Featured in InvestmentPitch Media Video
Via Investor Brand Network
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next 
Via Benzinga
Exposures Product Safety

Performance

YTD
+61.92%
+61.92%
1 Month
+5.04%
+5.04%
3 Month
+2.46%
+2.46%
6 Month
-20.38%
-20.38%
1 Year
+50.60%
+50.60%

More News

Read More
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Interim Results from FIH Clinical Trial of Lucid-MS
Via Investor Brand Network
FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated
Via ACCESSWIRE
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Coverage Initiated by Singular Research
Via Investor Brand Network
FSD Pharma Announces Analyst Coverage Initiated by Singular Research
Via ACCESSWIRE
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
Via Benzinga
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
Via Benzinga
FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW)
From FSD Pharma Inc.
Via Business Wire
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
Via Benzinga
Topics Cannabis Economy
Exposures Cannabis Interest Rates
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Present Phase 1 Data on Lucid-MS at Milan Peer Conference
Via Investor Brand Network
FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023
Via ACCESSWIRE
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
Via Benzinga
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) UNBUZZD Definitive Agreement Featured by Investment Pitch Media
Via Investor Brand Network
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) UNBUZZD Definitive Agreement Featured by Investment Pitch Media
Via Investor Brand Network
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
Via Benzinga
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Launch UNBUZZD
Via Investor Brand Network
FSD Pharma Signs Definitive Agreement to Launch UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink
Via ACCESSWIRE
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
Via Benzinga
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Arbitration Panel Finding in Syneos Health (NASDAQ: SYNH) Proceeding
Via Investor Brand Network
Exposures Product Safety
Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201
From FSD Pharma Inc.
Via Business Wire
FSD Pharma Retains Christian Attar Law and Team of Experts to Lead Preliminary Investigation of Possible Naked Short Selling and Manipulation in its stock
From FSD Pharma Inc.
Via Business Wire
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
Via Benzinga
FSD Pharma Appoints Zeeshan Saeed as Chief Executive Officer, Anthony Durkacz to Serve as Executive Co-Chairman of the Board of Directors
From FSD Pharma Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.